Moderna Inc
MRNA24.770USD
-0.190-0.76%
Cierre 11/14, 16:00（ET）Cotizaciones retrasadas 15 min
9.69BCap. mercado
PérdidaP/E TTM
Más Datos de Moderna Inc Compañía
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Información de Moderna Inc
Símbolo de cotizaciónMRNA
Nombre de la empresaModerna Inc
Fecha de salida a bolsaDec 07, 2018
Director ejecutivoMr. Stephane Bancel
Número de empleados5800
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 07
Dirección325 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono16177146500
Sitio Webhttps://www.modernatx.com/
Símbolo de cotizaciónMRNA
Fecha de salida a bolsaDec 07, 2018
Director ejecutivoMr. Stephane Bancel
Ejecutivos de Moderna Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
COVID
114.00M
0.00%
RSV
0.00
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
88.00M
77.19%
Rest of the World
26.00M
22.81%
Europe
0.00
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
COVID
114.00M
0.00%
RSV
0.00
0.00%
Estadísticas de accionistas
Actualizado: hace 23 horas
Actualizado: hace 23 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Otro
70.73%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Otro
70.73%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
38.96%
Investment Advisor/Hedge Fund
14.16%
Hedge Fund
10.34%
Corporation
4.63%
Research Firm
4.51%
Individual Investor
2.54%
Bank and Trust
1.37%
Venture Capital
1.19%
Pension Fund
1.17%
Otro
21.14%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1925
289.85M
74.21%
-20.82M
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
41.62M
10.7%
+1.37M
+3.40%
Jun 30, 2025
Baillie Gifford & Co.
22.09M
5.68%
-2.85M
-11.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.64M
5.05%
+1.76M
+9.86%
Jun 30, 2025
State Street Investment Management (US)
17.27M
4.44%
-507.93K
-2.86%
Jun 30, 2025
Two Sigma Investments, LP
14.77M
3.8%
+6.51M
+78.82%
Jun 30, 2025
Fidelity Management & Research Company LLC
19.46M
5%
-1.37M
-6.56%
Jun 30, 2025
Geode Capital Management, L.L.C.
8.88M
2.28%
+1.42M
+19.05%
Jun 30, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.37%
+160.31K
+1.77%
Mar 05, 2025
Theleme Partners LLP
7.87M
2.02%
+626.42K
+8.65%
Jun 30, 2025
D. E. Shaw & Co., L.P.
7.46M
1.92%
+1.83M
+32.42%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
3.76%
Global X Genomics & Biotechnology ETF
3.46%
First Trust NYSE Arca Biotechnology Index Fund
2.38%
SPDR S&P Biotech ETF
2.2%
VanEck Biotech ETF
1.84%
Invesco S&P 500 Equal Weight Health Care ETF
1.75%
Langar Global HealthTech ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.57%
ROBO Global Healthcare Technology & Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.42%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción3.76%
Global X Genomics & Biotechnology ETF
Proporción3.46%
First Trust NYSE Arca Biotechnology Index Fund
Proporción2.38%
SPDR S&P Biotech ETF
Proporción2.2%
VanEck Biotech ETF
Proporción1.84%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.75%
Langar Global HealthTech ETF
Proporción1.61%
Virtus LifeSci Biotech Products ETF
Proporción1.57%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.55%
WisdomTree BioRevolution Fund
Proporción1.42%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
